Mybl2 peptides and vaccines containing the same

An oligopeptide and amino acid technology, applied in the field of drugs for the treatment and prevention of tumors, can solve problems such as low objective response rate

Inactive Publication Date: 2012-10-24
ONCOTHERAPY SCI INC
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, only low objective response rates have been observed so far in these cancer vaccine trials (NPL 11, Belli F et al., J Clin Onco...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mybl2 peptides and vaccines containing the same
  • Mybl2 peptides and vaccines containing the same
  • Mybl2 peptides and vaccines containing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0348] Materials and methods

[0349] cell line

[0350] Human B-lymphoblastoid cell line T2 (HLA-A2) and African green monkey kidney cell line COS7 were purchased from ATCC.

[0351] Candidate selection for peptides derived from MYBL2

[0352] Using "NetMHC3.0" combined with prediction server (http: / / www.cbs.dtu.dk / services / NetMHC / ) (Buus et al. (Tissue Antigens., 62:378-84, 2003), Nielsen et al. (Protein Sci., 12:1007-17, 2003, Bioinformatics, 20(9):1388-97, 2004)) predicted 9-mer and 10-mer peptides derived from MYBL2 that bind the HLA-A*0201 molecule. These peptides were synthesized by Biosynthesis (Lewisville, Texas) according to standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry, respectively. Peptides were dissolved in dimethyl sulfoxide (DMSO) at 20 mg / ml and stored at -80°C.

[0353] In vitro CTL ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof.

Description

technical field [0001] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides that are extremely useful as cancer vaccines, and drugs for treating and preventing tumors. [0002] priority [0003] This application claims the benefit of US Provisional Application No. 61 / 266,871, filed December 4, 2009, the entire contents of which are hereby incorporated by reference. Background technique [0004] It has been demonstrated that CD8-positive CTLs can recognize epitope peptides derived from tumor-associated antigens (TAAs) appearing on major histocompatibility complex (MHC) class I molecules, and then kill tumor cells. Since the discovery of the first example of TAA—the melanoma antigen (MAGE) family, people have mainly used immunological methods (NPL 1: Boon T, Int J Cancer 1993May 8,54(2):177-80; NPL 2: Boon T & van der Bruggen P, J Exp Med 1996 Mar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/06A61K39/00A61P35/00C12N15/09
CPCA61K39/0011C07K14/4748C07K14/82A61P35/00A61P37/04A61P43/00
Inventor 中村佑辅角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap